Kodiak Sciences, Inc. (KOD)
39.12
-0.21
(-0.53%)
USD |
NASDAQ |
Aug 27, 16:00
39.12
0.00 (0.00%)
After-Hours: 17:31
Kodiak Sciences Enterprise Value : 2.498B for Aug. 26, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 26, 2026 | 2.498B |
| August 25, 2026 | 2.506B |
| August 24, 2026 | 2.365B |
| August 21, 2026 | 2.435B |
| August 20, 2026 | 2.530B |
| August 19, 2026 | 2.544B |
| August 18, 2026 | 2.581B |
| August 17, 2026 | 2.602B |
| August 14, 2026 | 2.625B |
| August 13, 2026 | 2.539B |
| August 12, 2026 | 2.754B |
| August 11, 2026 | 2.673B |
| August 10, 2026 | 2.754B |
| August 07, 2026 | 2.877B |
| August 06, 2026 | 2.879B |
| August 05, 2026 | 2.767B |
| August 04, 2026 | 2.722B |
| August 03, 2026 | 2.529B |
| July 31, 2026 | 2.639B |
| July 30, 2026 | 2.697B |
| July 29, 2026 | 2.541B |
| July 28, 2026 | 2.558B |
| July 27, 2026 | 2.660B |
| July 24, 2026 | 2.629B |
| July 23, 2026 | 2.604B |
| Date | Value |
|---|---|
| July 22, 2026 | 2.661B |
| July 21, 2026 | 2.692B |
| July 20, 2026 | 2.595B |
| July 17, 2026 | 2.706B |
| July 16, 2026 | 2.619B |
| July 15, 2026 | 2.692B |
| July 14, 2026 | 2.745B |
| July 13, 2026 | 2.609B |
| July 10, 2026 | 2.622B |
| July 09, 2026 | 2.545B |
| July 08, 2026 | 2.580B |
| July 07, 2026 | 2.433B |
| July 06, 2026 | 2.353B |
| July 02, 2026 | 2.448B |
| July 01, 2026 | 2.367B |
| June 30, 2026 | 2.475B |
| June 29, 2026 | 2.332B |
| June 26, 2026 | 2.220B |
| June 25, 2026 | 2.105B |
| June 24, 2026 | 2.224B |
| June 23, 2026 | 2.289B |
| June 22, 2026 | 2.263B |
| June 18, 2026 | 2.233B |
| June 17, 2026 | 2.206B |
| June 16, 2026 | 2.034B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 4.209B |
| Alnylam Pharmaceuticals, Inc. | 31.64B |
| Anika Therapeutics, Inc. | 276.98M |
| Savara, Inc. | 1.010B |
| Vericel Corp. | 2.104B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -65.64M |
| Total Expenses (Quarterly) | 65.64M |
| EPS Diluted (Quarterly) | -1.048 |
| Earnings Yield | -10.72% |
| Normalized Earnings Yield | -10.72 |